Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study

Background: Angiotensin Converting Enzyme inhibitors (ACEis) and beta-blockers (BB) are suggested to prevent and treat trastuzumab-related cardiac toxicity. We performed a prospective clinical trial in women experiencing mild cardiac toxicity (MCT) while on adjuvant treatment with trastuzumab. Metho...

Full description

Bibliographic Details
Main Authors: Elena Geuna, Pasquale Lombardi, Rossella Martinello, Davide Garino, Alessandro Bonzano, Danilo Galizia, Annamaria Nuzzo, Paola Berchialla, Paolo Becco, Monica Mangioni, Lorena De Zarlo, Filippo Montemurro
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
breast cancer
trastuzumab
cardiac toxicity
enalapril
carvedilol
ace inhibitors
beta blockers
Online Access:https://www.mdpi.com/2072-6694/12/2/327

Internet

https://www.mdpi.com/2072-6694/12/2/327

Similar Items